StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) income statement

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$27.65−4.08 (-12.86%)

Close on Nov 20, 2026Market cap $1.35BP/E –Yield –

UroGen Pharma Ltd. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
90.8%
Operating margin
-35.3%
Net margin
-51.7%
Return on equity, FY2025
268.6%

Financial strength

Current ratio
3.80
Debt to equity
-1.43
Debt to assets
74.7%
Cash to current liabilities
127.8%

Valuation

P/E ratio
–
Price to sales
7.16
Price to book
–
Dividend yield
–

See a number that looks wrong?